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Multi-targeted treatmentsa b s t r a c t
While high-throughput drug screening offers possibilities to profile phenotypic responses of hundreds of
compounds, elucidation of the cell context-specific mechanisms of drug action requires additional anal-
yses. To that end, we developed a computational target deconvolution pipeline that identifies the key tar-
get dependencies based on collective drug response patterns in each cell line separately. The pipeline
combines quantitative drug-cell line responses with drug-target interaction networks among both
intended on- and potent off-targets to identify pharmaceutically actionable and selective therapeutic tar-
gets. To demonstrate its performance, the target deconvolution pipeline was applied to 310 small mole-
cules tested on 20 genetically and phenotypically heterogeneous triple-negative breast cancer (TNBC) cell
lines to identify cell line-specific target mechanisms in terms of cytotoxic and cytostatic drug target vul-
nerabilities. The functional essentiality of each protein target was quantified with a target addiction score
(TAS), as a measure of dependency of the cell line on the therapeutic target. The target dependency pro-
filing was shown to capture inhibitory information that is complementary to that obtained from the
structure or sensitivity of the drugs. Comparison of the TAS profiles and gene essentiality scores from
CRISPR-Cas9 knockout screens revealed that certain proteins with low gene essentiality showed high tar-
get addictions, suggesting that they might be functioning as protein groups, and therefore be resistant to
single gene knock-out. The comparative analysis discovered protein groups of potential multi-target syn-
thetic lethal interactions, for instance, among histone deacetylases (HDACs). Our integrated approach
also recovered a number of well-established TNBC cell line-specific drivers and known TNBC therapeutic
targets, such as HDACs and cyclin-dependent kinases (CDKs). The present work provides novel insights
into druggable vulnerabilities for TNBC, and opportunities to identify multi-target synthetic lethal inter-
actions for further studies.
 2020 The Author(s). Published by Elsevier B.V. on behalf of Research Network of Computational and
Structural Biotechnology. This is an open access article under the CC BY-NC-ND license (http://creative-
commons.org/licenses/by-nc-nd/4.0/).1. Introduction
In phenotype-based drug discovery, high-throughput screening
(HTS) is often used to profile the sensitivity or toxicity of hundreds
of drug molecules across panels of cell lines or patient-derived
samples to identify a few hit compounds with desired response
profiles for further development [1,2]. Compared to the target-
based drug discovery, which starts from an individual, disease-
related protein, phenotype-based drug discovery assays profile
the complex cellular system as a whole, with the aim to revealsmall molecules or other bioactive molecules causing specific cel-
lular phenotypes [3]. However, the underlying cellular response
patterns and target mechanisms of the screened drugs often
remain unknown in HTS experiments. Therefore, target deconvolu-
tion approaches are needed to map the observed cellular responses
of drugs to the underlying drug-target interaction networks, with
the aim to dissect the cell context-specific mechanisms of the
drugs’ action in terms of their on- and off-target profiles [3]. Vari-
ous experimental methods have been used to identify potential
therapeutic targets, such as chemical proteomics, gene expression
response profiling and CRISPR-Cas9 knockout screening [4]. How-
ever, there is a need for systematic and cost-effective target decon-
volution by computational means.
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classes, a single drug may have potency against multiple protein
targets. For instance, protein kinase inhibitors are tractable in
drug development and play a role in a wide range of diseases,
such as cardiovascular disorders and cancers [5,6]. However, pro-
tein kinase domains share structural and sequence similarity, and
most kinase inhibitors bind to conserved ATP-binding pockets,
which leads to prevalent target promiscuity and polypharmaco-
logical effects. Therefore, kinase inhibitors in particular require
multi-target deconvolution approaches. The non-intended targets,
termed as off-targets, are one of the main reasons for adverse
drug reactions [7,8]. However, in some cases, especially in com-
plex diseases such as cancer, off-targeting effects of kinase inhi-
bitors may also lead to increased therapeutic effects through
multi-targeting several cancer survival pathways [9]. In particular
combinations of oncogene co-inhibitions may lead to selective
killing of cancer cells, a concept generally termed as synthetic
lethality [10,11], which can be harnessed through polypharmaco-
logical effects [12]. However, systematic identification of syn-
thetic lethal interactions among multiple targets has remained
difficult due to complex and context-specific interaction
networks.
To facilitate the phenotype-based and context-specific drug dis-
covery process, we implemented a computational target deconvo-
lution pipeline (see Fig. 1). High-throughput drug screening assays
are first quantified using response metrics, such as drug sensitivity
score (DSS) [13], which provide a robust summary of the drug
dose-responses in each cell line [14,15]. Next, we developed a con-
fidence ranking approach for the heterogeneous drug-target bind-
ing information extracted from public target databases, such as
ChEMBL [16] and Drug Target Commons [17], to map the observed
drug responses to most reliable and potent target activities. Target
addiction score (TAS) [18] is then calculated for each target and cell
line separately, based on the drug-target interaction networks, to
quantify the functional importance of each target protein for the
particular cell line inhibition. To provide statistical support for
these druggable target dependencies, we implemented an empiri-
cal inference approach that uses a permutation procedure to statis-
tically test the significance of an observed TAS level by generating
null distribution based on randomized drug-target interaction net-
works. The novel permutation testing approach makes it possible
to compare response profiles from HTS experiments with different
sizes of compound libraries.
We applied the target deconvolution pipeline to identify func-
tionally important target proteins in 20 triple negative breast can-
cer (TNBC) cell lines. TNBC is a highly aggressive subtype of breast
cancer which is devoid of the hormonal receptors and human epi-
dermal growth factor 2 (HER2). TNBC also lacks effective pharma-
ceutically targetable genetic alterations. Even though there are
targeted therapies, such as poly (ADP-ribose) polymerase (PARP)
inhibitors, standard chemotherapy often remains the only drug
treatment option for TNBC [19,20]. However, since TNBC patients
often have worse outcomes for chemotherapy [21,22], there is an
intensive search for more efficient and targeted therapies for TNBC
[23,24]. TNBC is a highly heterogeneous breast cancer subtype,
hence demands stratified treatment options. To aid TNBC thera-
peutics stratification, the target dependency profiles of the TNBC
cell lines, calculated based on HTS of 310 small molecules, were
further correlated with gene essentiality profiles from CRISPR-
Cas9 knock-out experiments. Clustering of the therapeutic targets
based on drug-protein interaction profiles revealed protein groups
that are resistant to single-gene knockout, hence providing insights
into the druggable vulnerabilities for TNBC, and opportunities to
identify multi-target synthetic lethal interactions for further
studies.38202. Results
We screened 20 TNBC cell lines using a drug library of 310 small
molecules, which includes both approved drugs and investiga-
tional compounds (Fig. S1). Two types of cell-based in vitro assays
were conducted to profile drug-induced cellular phenotypes in 2D
assays, namely cell viability and cell toxicity assays (see Materials
and Methods). DSS was calculated to quantify both drug-induced
cell viability inhibition and cytotoxicity. The TNBC cell lines exhib-
ited heterogeneous drug responses across 310 oncology com-
pounds in terms of both viability inhibition and cytotoxicity
phenotypes [25]. This alarming result calls for the cell line-
specific target deconvolution to better understand the cell
context-specific target mechanisms of the drugs and to identify
effective and selective therapeutic targeting options for stratified
TNBC treatments.
2.1. Systematic mapping of drug-target interactions for target
deconvolution
Construction of reliable drug-target interaction networks is hin-
dered by multiple bioactivities measured for the same drug-target
pair, reported by different labs and studies using various experi-
mental conditions. To construct systems-wide drug-target interac-
tion networks for target deconvolution, we therefore summarized
the most confident drug-target bioactivities based on confidence
rankings of all the experimental bioactivity measurements
between the 310 drugs and 632 targets retrieved from the DTC
database (see Materials and Methods). The confidence ranking of
the various bioactivity categories was based on the variability of
replicated bioactivity measurements within each category, esti-
mated by the median absolute deviation (MAD). For 4995 bioactiv-
ities (36%), with annotated standard type and assay format
available, we obtained a detailed confidence ranking across both
biochemical and cell/tissue-based assays (Table 1). The confidence
ranking for the remaining 8790 bioactivities (64%), for which only
known standard type annotation was available, remained generally
very similar (Table S2).
This confidence ranking enables one to carry out comprehen-
sive target deconvolution across wide libraries of drugs and targets
by integration of bioactivity data from various target profiling
assays, even in the absence of all the experimental factors of the
assays affecting their performance. The median of bioactivities
from the most confident bioassay categories was here considered
as the summarized bioactivity for each single drug-target pair
(see Materials and Methods). Fig. 2 shows selected examples of
drug-target pairs with their original and summarized bioactivities.
It was observed that under different types of assay and detection
technologies, the bioactivities for the same drug-target pair can
easily span across two orders of magnitude in their potency. Such
heterogeneity in the original bioactivities hinders the target decon-
volution process, whereas the summarized bioactivities based on
the confidence rankings and relatively standardized bioactivity
levels enable construction of more reliable drug-target interaction
networks, and further target deconvolution statistical analysis
based on the most confident drug-target interactions only.
Interestingly, the bioactivity summarization process revealed
that while the intended targets of drugs often have higher activi-
ties across their multiple on- and off-targets, as was expected,
there exists also several drugs for which the nominal target activ-
ities are actually weaker than the median activities among their
off-targets (Fig. 3, upper panel). This suggests that polypharmaco-
logical and drug off-target effects play an important role in the
drug-induced cell line response phenotypes, as was argued also
in the recent study [11], and therefore these potent off-target
Fig. 1. Schematic overview of the target deconvolution workflow implemented in the study.
Table 1
Ranking of bioactivity assays based on median absolute deviation (MAD).
Standard type Assay format Median MAD Confidence Rank
Ki Biochemical 0,005 1
Kdapp Cell-free 0,013 2
Kd Cell-based 0,021 3
Kd Biochemical 0,038 4
IC50 Cell-based 0,064 5
Ki Cell-based 0,074 6
EC50 Cell-based 0,076 7
IC50 Biochemical 0,079 8
Kd Physiochemical 0,080 9
IC50 Tissue-based 0,115 10
IC50 Cell-free 0,126 11
EC50 Tissue-based 0,235 12
T. Wang, P. Gautam, J. Rousu et al. Computational and Structural Biotechnology Journal 18 (2020) 3819–3832effects needs to be taken into account in the target deconvolution
process. In general, the bioactivity measurements using various
multi-dose assay types (Kd, Ki, IC50 and EC50) show relatively large
variability also within the categories of both nominal on-targets3821and non-intended off-targets (Fig. 3). This further motivates the
use of an effective bioactivity summarization process that uses
only the most confident bioactivity measurements when con-
structing drug-target networks for target deconvolution.2.2. Characterization of the compound and target activity spaces of the
screening library
To focus on potent compound-target activities, we filtered out
all non-potent drug-target interactions and used only those pairs
with a summarized bioactivity < 1000 nM in the target deconvolu-
tion. This activity filtering resulted in 4 276 unique bioactivities
quantifying potent binding interactions between the 310 drugs
and 632 targets. The distributions of bioactivities before and after
the summarization and activity filtering show that the activity fil-
tering process effectively eliminates the non-potent interactions,
whereas the right-hand tail of active interactions has a relatively
similar shape (Fig. 4A-B). When using the rather liberal activity
cut-off of 1000 nM, the average number of targets per drug was
4 in our dataset, although there were also compounds with more
Fig. 2. Original and summarized bioactivities for four example drug-target pairs, where various assay types for the same pair are separated on the x-axis and the detection
technologies used in the target profiling studies are indicated with colour coding of the bioactivity measurements (points). Higher values on y-axis indicate more potent
compound-target binding affinities. TFR, Time Resolved Fluorescence; qPRC, quantitative Polymerase Chain Reaction.
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spectrum of polypharmacological effects for many of the com-
pounds in our library, consisting mostly of promiscuous kinase
inhibitors (Fig. S1), which are known for their promiscuity and
therefore require a multi-target deconvolution approach.
To obtain a more holistic view of the distribution of compound-
target profiles in the dataset, the screened drug-target space was
visualized with unsupervised t-Distributed Stochastic Neighbour-
ing Embedding (t-SNE) mapping and hierarchical clustering
(Fig. 5). Fig. 5A visualizes the underlying space of the screened
drugs spanned by their binary target profile similarities (see Mate-
rials and Methods). Color-coding indicates the structural Tanimoto
similarities of the nearest neighbour of each compound calculated
using the MACCS fingerprints. The drug mapping reveals that many
of the compounds with similar target profiles are also structurally
similar (e.g., selumetinib and binimetinib). Fig. 5B shows the quan-
titative compound-target bioactivity matrix, where the protein tar-
gets are color-coded based on the protein superfamilies. This
systematic analysis illustrates how the established drug and target
classes are not very well clustered together in terms of the drug-
target bioactivities, thus indicating that the bioactivity data pro-
vide additional information on the drugs’ mode of action, not cap-
tured by their known mechanistic classes.2.3. Functional dependencies and druggable vulnerabilities of TNBC
cell lines
To quantify the functional importance of protein targets for the
drug-cell line responses, TAS levels were calculated for each of the
632 targets, as the overall cell inhibition of compounds targeting3822the particular protein, separately for the 20 TNBC cell lines, based
on the summarized and filtered drug-target bioactivities (see
Materials and Methods). Importantly, a permutation testing proce-
dure was implemented to assess the statistical significance of the
observed TAS values by means of calculating empirical p-values
based on permutation null distribution. The correlation of TAS val-
ues from the two cell assays were compared to that of the original
DSS values in the individual TNBC cell lines (Fig. 6). Since many of
the drug compounds in our library have multiple active targets,
and most of the targeted drugs exhibit cytostatic effect, the DSS
values are expected to show relatively poor correlation between
the toxicity and viability assays (Fig. 6A). However, in selected cell
lines (e.g., CAL-51, DU4475, HCC1395), the TAS profiles based on
the viability and toxicity assays showed correlated patterns
(Fig. 6B), suggesting the TAS profiles were able to capture the com-
mon phenotypic changes in these cell line responses based on the
two cell-based assays.
To further investigate how the bioactivity-based target profiles
contribute to cell-based viability and toxicity responses of the
drugs, we took example compound pairs from Fig. 5A, and further
analysed their TAS and DSS patterns across the TNBC cell lines. In
the first example of two drugs, luminespib and BIIB021, have
rather dissimilar molecular structures, but they still showed simi-
lar target profiles (Fig. 7A). Notably, their common targets,
HSP90AB1, HSP90B1, HSP90AA1 and TRAP1, were identified as
the key dependencies in multiple cell lines (Fig. 7B), which accu-
rately explained the drug response patterns across the heteroge-
neous TNBC cell lines (Fig. 7C). The second example shows how
two structurally similar drugs, selumetinib and binimetinib
Fig. 3. Comparison of bioactivities of nominal targets and other targets for four example drugs: fenofibrate (nominal target: PPARA, Peroxisome proliferator-activated
receptor alpha), plerixafor (nominal target: CXCR4, C-X-C motif chemokine receptor type 4), methotrexate (nominal target: DHFR, Dihydrofolate reductase), and albuterol
(nominal target: ADRB2, Adrenoceptor Beta 2). The points in the boxplots indicate the dose-response bioactivity measurements before summarization of data from multiple
target profiling studies and replicate measurements in DTC. The bioactivity distributions of nominal and other targets were compared by Mann-Whitney U test.
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(Fig. 5A), presented also with very similar TAS profiles for their two
common targets, MAP2K1 and MAP2K2 (Fig. S2B). These examples
demonstrate how the functional similarity based on the target
dependencies provides further insights into the cell line-specific
mechanisms of action of drugs, something that cannot be inferred
from the structural similarity alone, or from the cell context-
agnostic target profiles without using the TAS calculations.2.4. Identification of key targets in each TNBC cell line based on drug
and CRISPR screens
To identify context-specific therapeutic targets for TNBC, we
calculated TAS values and empirical p-values that identified cell
line-specific protein targets across the 20 TNBC cell lines. Targets3823having a high TAS, along with a small empirical p-value, were iden-
tified as functionally important targets for a given cell line. As
expected, the cell line-specific TAS profiles were able to identify
a number of well-established TNBC driver genes (Table 2), such
as AKT1 and AKT2 for CAL-148 and MFM-233; MAP2K1, MAP2K2,
BIRC2, XIAP for MDA-MB-231 [26]. Furthermore, targeting the
HDAC family and proteasome subunits (PSMB) tend to inhibit most
of the TNBC cell lines, whereas CDK families were mostly specific
to HCC1935. We also identified a number of so-far unexplored
functionally important targets, such as STK11 for HCC-1395, TACR2
for BT-20 and PDXK for MFM-223 (Fig. 8; see also Fig. 6B), which
warrant further studies by orthogonal cell assays. We note that
some of the established drivers of the TNBC cell lines were not
identified using the drug-induced TAS profiles (Table 2), which is
Fig. 4. A. Distribution of bioactivities before (n = 23,469) and after (n = 8383) the summarization process between 310 drugs and 782 targets. B. Distribution of bioactivities
before (n = 8383, 310 drugs and 782 targets) and after (n = 4276, 310 drugs and 632 targets) the activity filtering (<1000 nM) process. C. Distribution of the number of potent
drugs inhibiting each target after the summarization process and applying a 1000 nM activity cut-off for filtering, which led to a total of 632 potent targets of the 310 drugs;
D. Distribution of the number of targets per drug after the bioactivity summarization and activity filtering process. Bioactivities larger than 1000 nM were regarded as non-
potent, and were therefore not used in the further target deconvolution and other downstream analyses. The peak in the distribution of panel A corresponds to many
10000 nM values used in kinome target screens to represent non-active pairs.
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than cell viability or death captured by our drug sensitivity assays.
Notably, 56% of the functionally significant targets showed also
elevated expression in the basal-like breast cancer patient samples
(Fig. S3).
To make a more systematic analysis of the functional target
dependency levels, TAS results were further corroborated by gene
dependency scores derived from CRISPR-Cas9 gene knockout
experiments in the same cell lines [27,28]. If a single gene knock-
out leads to reduced cell viability or cell death, then such gene is
called as essential for the particular cell line, and thus has a more
negative gene dependency score. Fig. 9 compares the TAS and gene
dependency scores for each of the 632 targets in two example cell
lines, BT-549 and HCC-1143. Surprisingly, many protein targets
that had high TAS were associated with relatively high gene depen-
dency scores, indicating that these targets are functionally essen-
tial in the cell context-specific drug mode-of-action, but not
essential in terms of genetic knockout of the single genes. In fact,
most of the protein targets with statistically significant TAS levels
had close to zero gene dependency scores. This implies that these
proteins may function as a group (or complex) when contributing
to drug-cell line responses, since single knockout of any of these
proteins shows only a limited impact on cell viability. We thus
hypothesized that these functionally important protein groups that
are resistant to single-gene knockout may pinpoint potential
multi-target synthetic lethal interactions for the specific cell lines.
For the identification of multi-protein target groups, we
explored how to make use of the pharmacological target depen-
dency profiles of single drugs that modulate the function of several
proteins simultaneously to exert multi-target co-inhibition effect.
Such polypharmacological effects of promiscuous drugs are cap-
tured by the potent off-target interactions used in the TAS calcula-
tion, while being mostly missed in the single-gene CRISPR-Cas93824knockout screens. To more systematically study such multi-
target interactions, we clustered the protein targets based on the
potent drug-target interactions, with the aim to find protein target
groups sharing common drugs as inhibitors. A number of protein
groups were manually selected during the clustering process as
their occurrence remains consistent across various parameters
used in the t-SNE analyses (see Materials and Methods). One such
protein group consisted of histone deacetylase (HDAC) enzymes
(HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8,
HDAC9, HDAC10 and HDAC11, see Fig. S4). These enzymes are
known to function in concert to remove acetyl groups from an
amino acid on a histone, and may therefore jointly contribute to
cell viability and selective killing. Based on these results, pan-
HDAC inhibitors warrant further testing as potential multi-target
co-inhibitors of HDAC synthetic lethal partners toward effective
and stratified TNBC treatments.3. Conclusions
We have developed a computational target deconvolution pipe-
line that implements several analysis tools for target dependency
profiling, ranging from reliable construction of drug-target interac-
tion networks to statistical analysis of the observed target addic-
tion levels. We demonstrated the operation of the pipeline in the
context of highly heterogeneous TNBC cell lines that require cell
line-specific analysis of drug and target vulnerabilities. The pipe-
line is expected to prove of value in multiple precision medicine
applications also beyond target dependency profiling. For instance,
comprehensive and confident compound-target interactions
should prove useful also for predicting the phenotypic effects of
combinatorial inhibitions [29,30], as well as to help manage poten-
tial side effects of combinatorial therapies [31].
Fig. 5. A. t-SNE mapping of the 310 drugs based on the similarity of their binary
target profiles, where drugs are color-coded by structural similarities of their
neighbour compounds. B. Quantitative drug-target bioactivity matrix between 310
drugs and 632 targets, where the broad target and drug classes are marked with
color-coding. NHR, Nuclear hormone receptors; GPCR, G protein-coupled receptors.
The matrix includes the 4 276 unique bioactivities after bioactivity summarization
and activity filtering, which covers 2% of the full drug-target matrix (the remaining
entries of the matrix are either non-measured pairs, based on DTC data, or non-
potent pairs, that is, summarized bioactivity >1000 nM).
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target bioactivity assays, both in cells and tissues, which are based
on either biochemical or cell/tissue-based assay formats. The bio-
chemical and cell-free assays are relatively straightforward in
practice and can inform us about the specificity of compound-
target interaction, whereas cell-based or physiochemical assays
provide also physiological information of the compound-target
binding. Furthermore, cell-based compound sensitivity assays cap-
ture the cell-specific characteristics of the compounds, such as
their efficacy, toxicity and other cellular phenotypes, but these
cannot quantify so accurately the specificity or selectivity of the
compound-target interaction in the host cells. All these assays have
factors that lead to variability and affect the consistency of target
activity and cellular outcomes. In biochemical assays, for instance,
factors such as pH, temperature, instrumentation, reagent charac-
teristics and order of addition plays a vital role. Similarly, in cell-
based assays, culture conditions such as humidity, temperature,
culture media, serum, culture vessel, passage number, and cell
cycle play a pivotal role.
There are also some notable differences between the 2D and 3D
compound sensitivity assay formats. For instance, the 2D system3825has a homogeneous population of proliferating cells grown in
monolayer or suspension, and thereby receiving uniform supply
of nutrients or exposure to the compounds. In contrast, 3D system
comprises of cells in various stages, including proliferating, quies-
cent, apoptotic, necrotic and hypoxic stages, as well as different
architectures, which results in rather different responses towards
the compound treatment as compared to the 2D assays. Both assay
outcomes also depend on the chosen time period of drug exposure
(72 h in the present study). The more complex 3D systems, such as
co-cultures or tissue slices, capture even more heterogenous cell
types, cell-cell and cell-matrix interactions, which also affect the
compound responses. However, the main limitation of the 3D cul-
ture systems is that they are currently not compatible with high-
throughput screening, which is important for systematic target
deconvolution approaches and the main focus of this work.
Currently, there are not comprehensive enough datasets from
any single assay type to cover all the relevant compounds and tar-
gets for systematic target deconvolution. Rather, compound-target
bioactivity data are scattered in various databases, such as DTC and
ChEMBL, that collect bioactivity data reported by different labs and
studies using various experimental conditions. Therefore, in the
absence of the knowledge of experimental factors affecting the
assay outcomes, we performed in this work statistical consistency
analysis to compare the various assay types in terms of their repro-
ducibility and confidence (Table 1). This analysis can be readily
extended once new assay types become available. This is one of
the benefits of our generic target deconvolution pipeline that is
applicable to any target profiling and compound sensitivity assays.
We believe that accurate target identifications from the simpler
experimental systems are critical for making translational discov-
eries for in vivo validations in animal and clinical studies in the
future.
Empirical p-value calculation based on permutation testing was
shown here to provide important information on the statistical
support for an observed TAS level, e.g., when comparing TAS values
that are based on different numbers of potent drugs (Fig. 4C), or
across cell lines that show large variability in their sensitivity to
the drugs (Fig. 7C). The robustness of the empirical p-value calcu-
lation to different drug library sizes was further investigated by
subsampling drugs from the full library of 310 compounds. The
permutation procedure was carried out by randomizing the drug-
target links, while keeping the number of drugs fixed, in order to
test how many drugs per target is enough to produce a reliable sig-
nificance calculation. Comparing the p-value distribution from the
subsampled drug sets against the original p-value from the full
drug library indicated that the p-value calculation remains rela-
tively robust until as few as 20% of the drugs are used in the target
deconvolution (Fig. S5). Notably, already 2 active drugs per target
was enough to provide rigid null distributions for the observed
TAS values (Fig. S6). Smaller drug sets lead to fewer active drugs
inhibiting some of the targets, and therefore the TAS values
become increasingly dependent on a single or a few DSS values.
For protein targets with only 1 potent drug, the distribution of
the permuted TAS values closely resembles the distribution of
DSS values of the same cell line (Fig. S6), as expected, indicating
that such sparse drug-target interaction network in which each
compound is connected to single protein cannot provide enough
information for a reliable target deconvolution. We therefore rec-
ommend that for protein targets with permuted TAS values show-
ing a close to uniform distribution, the observed TAS value is not
reliable even if it has a significant p-value. With more potent drugs,
there is enough statistical variability for empirical p-value calcula-
tion (Fig. S6).
Our target deconvolution method successfully recovered sev-
eral well-known drivers of TNBC cell lines. Since HDACs regulate
gene expression and transcription, many HDAC inhibitors, such
Fig. 6. A, B. Scatter plots of drug sensitivity score (DSS) of the 310 drugs (points in panel A) and target addiction score (TAS) of the 632 targets (panel B) between cell viability
and cell toxicity assays calculated for the 20 TNBC cell lines (colours of the points). A higher DSS indicates increased sensitivity of a cell line to the particular drug, whereas a
higher TAS suggests a higher functional dependency of the cell line on a specific target. Selected targets are highlighted in panel B as known drivers or potential key targets of
the particular cancer cell lines with significant TAS value (p < 0.05).
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various cancer models and are currently undergoing clinical trials
(e.g., NCT03361800) for breast cancer treatment [32]. Similarly,
heat shock protein 90 (HSP90) is a protein class involved in regu-
lating stability, activation and maturation of effector molecules
driving many key signalling pathways, and hence explored as a tar-
get against TNBC since it disrupts multiple oncogenic pathways
[33,34]. CDKs are key regulators of cell cycle, and TNBCs have been
shown to be sensitive to CDK inhibitors [35,36]. For instance,
CDK4/6 are regarded as promising targets for TNBC, and thereby
extensively explored in the field [36–38]. We showed that TNBC
cell lines, such as HCC38 and HCC70, have a unique dependence
on CDK7, which can be harnessed as a selective therapeutic target
[39]. Furthermore, inhibition of CDK12 and CDK13 provides syner-
gistic effect on DNA damaging drugs or Poly (ADP-ribose) poly-
merase (PARP) inhibitors to induce TNBC cell death [40].
Inhibition of X-linked inhibitor of apoptosis (XIAP) in MDA-MB-
231 has been shown to sensitize breast cancer cells to chemother-
apies [41]. Aberrations in the phosphoinositide 3-kinase (PI3K)/
protein kinase B (AKT)/mechanistic target of rapamycin (mTOR)
pathway are also common in TNBC cell lines, and drugs targeting
proteins in this pathway are well-studied and developed, such as
PI3K and AKT inhibitors [42]. These and several other druggable
targets, such as Kinesin Family Member 11 (KIF11) [43] and Aurora
Kinase A (AURKA) [44], which were identified by the TAS analysis
(Table 2), demonstrated its robustness to identify both known and
novel functional addictions in individual cell lines.
Interestingly, the TAS analysis also identified several novel cell
line-specific targets to achieve both cell viability inhibition and cell
death. Some of the striking examples are tumour suppressor STK11
(upstream kinase of AMPK) for HCC-1395; a member of transmem-
brane G-protein coupled receptor TACR2, molecular motor protein
KIF11 for BT-20, mitochondrial molecular chaperone TRAP1 (heat
shock protein family) for DU4475; and kinase involved in vita-
minB6 metabolism PDXK for MFM-223. Both BT-20 and MFM-
223 were also identified to be affected by dual specificity protein
kinase CLK3. Similarly, intestinal serine/threonine kinase ICK was
identified to affect MFM-223, HCC-1395 and HCC-70. Therese so-
far unexplored target addictions warrant further studies. To under-
stand the target pathway dependencies, we mapped 632 targets,
pre-ranked by their TAS p-values from different cell lines, onto
KEGG pathways using Gene set enrichment analysis (GSEA)3826(Fig. S7). Significantly enriched pathways included AMPK sig-
nalling pathway, cell cycle, JAK-STAT signalling pathway, MAPK
signalling pathway, p53 signalling pathway, viral carcinogenesis,
inositol phosphate metabolism, and neuroactive ligand-receptor
interaction (FDR < 0.2). Most of the effector molecules driving
these pathways are known to be overexpressed in TNBC, making
them potential therapeutic targets for TNBC. For example, AMPKs
are relatively upregulated in TNBC as compared to non-TNBC
[45], STAT3 is known to be overexpressed and constitutively active
in TNBC [46], and reports show higher expression levels of MAPK in
TNBC [47]. Hence, the significant target pathways further corrobo-
rated that targets with significant TAS levels are intensively
involved in cell growth, apoptosis, and carcinogenesis. The main
reason why the alcoholism pathway was significant was due to
the enriched HDACs (Figure S7).
As a potential limitation, the current TAS profiling was not able
to identify NTRK3/FGFR2 in MFM-223 and MAP2K1/MAP2K2 in
MDA-MB-231 (Table 2). This is due to the general lack of selective
drugs against these targets, or because the particular cell line was
not sensitive to the potent drugs on average. For example, NTRK3
can be inhibited by 14 potent drugs in our library, with TAS of
4,66 and 1,17 from the cell viability and toxicity assays, respec-
tively. However, the average TAS in MFM-223, calculated based
on the 14 drugs in randomized drug-target interaction networks,
are higher (6,93 and 2,77 from the two assays, respectively), which
indicates that NTRK3 does not show statistically significant target
dependency in the current dataset. Similarly, our algorithm did not
capture CDK4/6 targets in the TNBC cell lines. This is because
CDK4/6 inhibitors in our screening drug library did not exhibit
strong effects on any of the TNBC cell lines in our panel. With larger
drug libraries and more potent drugs, it is expected that also these
established TNBC drivers could be identified using the target
dependency profiling using solely the drug screening assays. Alter-
natively, one could combine TAS profiling with other cell line-
specific experiments, such as gene expression or protein activity
profiles, to make use of the baseline molecular background of the
cell lines profiled before drug treatments. However, even if such
additional profiling datasets can add another layer of context-
specific information into the target inhibition analyses, these
methods also add further costs to the studies, and especially with
limited patient primary cells, one needs to carefully consider
which assays can be afforded and be applied within a clinically
Fig. 7. A. 2D structures of luminespib and BIIB021 with low Tanimoto similarity of 0.452; B. TAS of their common targets, HSP90AB1, HSP90B1, HSP90AA1 and TRAP1, based
on cell viability (left) and cell toxicity (right) assays; C. DSS of the drugs based on the viability and toxicity assays.
Table 2
Established drivers of TNBC cell lines and their TAS values calculated using cell viability and toxicity assays. Boldfacing indicates significant TAS values based on the permutation
testing.
Uniprot ID Gene symbol Cell line TAS viability P-value Viability rank TAS toxicity P-value Toxicity rank
P31749 AKT1 CAL-148 14,55 0,0050 14 17,77 0,0067 13
P31751 AKT2 CAL-148 17,90 0,0040 13 22,44 0,0041 8
P31749 AKT1 MFM-223 12,59 0,034 65 1,94 0,57 344
P31751 AKT2 MFM-223 15,38 0,022 48 2,76 0,40 246
P50613 CDK7 HCC-38 11,54 0,0014 5 6,39 0,022 26
P50613 CDK7 HCC-70 11,69 0,0028 9 3,42 0,0084 22
P98170 XIAP MDA-MB-231 24,60 0,0009 7 34,45 0,0000 1
Q13490 BIRC2 MDA-MB-231 23,00 0,0025 14 31,80 0,0002 4
P15056 BRAF DU-4475 13,57 0,055 62 10,84 0,011 22
Q16288 NTRK3 MFM-223 4,66 0,86 578 1,17 0,86 463
P21802 FGFR2 MFM-223 9,25 0,10 150 1,96 0,70 411
Q02750 MAP2K1 MDA-MB-231 6,58 0,22 180 3,71 0,31 97
P36507 MAP2K2 MDA-MB-231 6,44 0,28 220 5,13 0,17 51
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Fig. 8. Significant functionally important targets for each cell line (FDR < 0.2) based on cell viability (left) and toxicity (right) assays. Grey entries indicate non-significant cell
line-target pairs (FDR  0.2). Boldfacing indicates that the protein targets discovered in the cell line screens were overexpressed in the basal-like breast cancer patient
samples from TCGA (see Fig. S3).
T. Wang, P. Gautam, J. Rousu et al. Computational and Structural Biotechnology Journal 18 (2020) 3819–3832actionable timeframe. The drug screening assays are fast and prac-
tical, taking 3 days to profile and 1 additional day to analyse the
results.
There are many potential reasons why the target dependencies
discovered based on the 2D drug screening data in TNBC cell lines
do not necessary show as prognostic markers in breast cancer3828patient tumors (Fig. S8). First, like noted above, there are funda-
mental differences between the in vitro and in vivo treatment
responses. Second, target dependency is a cellular phenotype
quantified after the in vitro treatments, whereas gene expression
levels were measured in TCGA at baseline (before the patient treat-
ment or after standard chemotherapy). Even though TCGA is the
Fig. 9. A, B. Association between drug-induced functional dependency score (TAS) and gene dependency score from CRISPR-Cas9 screens across the 632 targets in BT-549 and
HCC-1143 cell lines. The significance of the TAS levels based on the two assays is shown in color-coding, where empirical p < 0.05 indicates a statistically significant target
(larger points).
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tain enough TNBC patients for statistically well-powered survival
analyses (only 98 basal-like samples annotated as TNBC). Never-
theless, we found that 56% of the target addictions discovered in
the TNBC cell lines had a higher median gene expression level in
the basal-like breast cancer samples (Fig. S3). This can be consid-
ered as relatively high statistical enrichment, given that our
approach was not designed for the identification of prognostic pro-
tein markers for breast cancer patients, but rather to identify func-
tionally important therapeutic targets based on cell line
pharmacological screens. We believe the ideal way of using the tar-
get addiction analysis for cancer patients will be based on system-
atic drug screening in the patient-derived primary cells ex-vivo.
The same target deconvolution approach can also be applied to
patient-derived cells, as was earlier shown in the context of tailor-
ing targeted treatments for patients with acute myeloid leukemia
[48,49].
A recent study by Ann Lin et al. found out that off-target toxicity
is a common mechanism of action of cancer drugs undergoing clin-
ical trials [11]. In particular, using single-target CRISPR-Cas9
assays, they demonstrated that a number of drugs exert their pri-
mary effects through other than their intended targets. This moti-
vates the use of integrated approaches, such as TAS, which
accounts for a wide spectrum of both weak and strong off-target
effects of drugs in the target deconvolution analysis. We further
demonstrated that single-gene dependency is not well-correlated
with the TAS scores, suggesting that the CRISPR-Cas9 knockout3829effect and the drug-induced inhibition effect are phenotypically
quite different. Specifically, TAS provides information of druggable
vulnerabilities of cell lines to a therapeutic targeting, as inferred
from multiple drugs inhibiting the particular protein, whereas
CRISPR-Cas9 provides information of the dependency of a cell line
to the loss of the protein function. As shown in our results (Fig. 9),
these two dependency scores provide complementary information
for the cell context-specific targeting. We argue that TAS may be
clinically more actionable since the druggability information is
included in the analyses, hence offering pharmacologically more
tractable cancer cell vulnerabilities for therapeutic targeting. For
future precision oncology studies, integrated pharmacological
and loss-of-function dependency analyses will likely offer
improved possibilities to select optimal interventions [50], either
functional or genetic perturbations, based on comprehensive infor-
mation of both on/off targets of the drug treatment or CRISPR-
Cas9-mediated genome engineering.4. Materials & methods
4.1. Summarization of drug-target interactions based on various
bioactivity measurements
The binding affinity of a drug against a protein target can be
assessed with different experimental protocols and assays, and in
various lab conditions. This results in multiple binding affinities
for the same drug-protein pair, reported by different labs and stud-
T. Wang, P. Gautam, J. Rousu et al. Computational and Structural Biotechnology Journal 18 (2020) 3819–3832ies, which hinders the integration of such bioactivity information
into computational biology studies. To address the heterogeneity
in reported bioactivity values, multiple binding affinity readouts
for a given pair were summarized into a single harmonized value
using our comprehensive DrugTargetCommons (DTC) database
[17]. In DTC, part of bioactivities are fully annotated according to
bioassay ontology (BAO), a simplified version of the minimum
information about a bioactive entity (MIABE). With BAO, various
bioassays conducted for the bioactivity assessments were anno-
tated based on bioassay format, type and detection technology.
Since the variability of replicated binding affinities from the same
type of bioassay indicates the stability of this bioassay across dif-
ferent labs and studies, we used this categorization of bioassays
to facilitate the summarization of various types of binding affini-
ties for a drug-target pair.
Formally, let D ¼ dif g denote the set of all drugs; T ¼ tj
 
denote the set of all targets; BT ¼ btnf g denote the set of all bioac-
tivity type categories; AF ¼ afmf g denote the set of all assay format
categories; AT ¼ atlf g denote the set of all assay type categories;
DT ¼ dtkf g denote the set of all detection technology categories;
and B ¼ bdi ;tj ;dtk ;atl ;afm ;btn jdi 2 D; tj 2
n
T; dtk 2 DT; atl 2 AT; afm 2 AF;
btn 2 BTgdenote the set of all existing bioactivities.
The confidence ranking of a given assay condition
(dtk; atl; afm; btn) is formally calculated as
rdtk ;atl ;afm ;btn ¼ MAD bdi ;tj ;dtk ;atl ;afm ;btn jdi 2 D; tj 2 T
n o 
ð1Þ
Based on (1), the confidence ranking of the bioactivity types BT
is defined as
R btnð Þ :¼ Median r dtk ; atl ; afm ; btn j dtk 2 DT; atl 2 AT; afm 2 AF
  
ð2Þ
The summarized bioactivity between drug di and target tj is
then calculated as
bsdi ;tj ¼ Median bdi ;tj ;dtk ;atl ;afm ;btn jbtn ¼ argminbtn2BTR;dtk 2 DT; atl 2 AT; afm 2 AF
n o 
ð3Þ
In this study, four types of dose-response bioactivities, namely
IC50, EC50, Ki and Kd, were extracted from the DTC database [17].
The confidence ranking of these bioactivity types was done sepa-
rately for each bioassay. For a given bioactivity type, bioactivities
were grouped by the assay condition. First, for each type of bioas-Fig. 10. Example of calculation of ranking score for the bioactivity type Ki. Median absolu
(e.g., Ki-Biochemical-Binding-Radiometry). Then, the median was used as the confidenc
median of all scores under this category. Confidence score of the bioactivity category Ki
3830say under each bioactivity type, bioactivities of all drug-target
pairs were normalized to range [0,1]. Next, median absolute devi-
ation (MAD) of multiple bioactivities was calculated as a variability
estimate for each drug-target pair in each bioassay category. The
median of all MADs within each bioassay type was used to evaluate
the stability of the particular bioassay (Eq. (1)). The median of the
median MADs across all bioassays within each bioactivity type was
finally considered for ranking the various bioactivity types (Eq.
(2)). Fig. 10 shows an example of calculating the ranking scores
for the bioactivity type Ki, where the bioactivities were grouped
based on assay type, assay format and detection technology. For
those bioactivities in DTC with annotated bioassay information,
the ranking of bioactivity type - assay format category was used
to rank all the bioactivities of a drug-target pair. For those bioactiv-
ities with unknown bioassay information, the ranking of bioactiv-
ity type was used instead.
Finally, the multiple bioactivities of each drug-target pair were
summarized into the median of bioactivities within the most con-
fident ranking bioassay category (Eq. (3)). The summarized bioac-
tivity values provide a standardized level of compound-target
activity with the unit of nM, and these levels were used in the tar-
get deconvolution and other downstream analyses.
4.2. Calculation of drug sensitivity and target addiction scores in the
TNBC cell lines
A panel of 20 breast cancer cell lines was screened against 310
oncology compounds in 5 different concentrations covering
10,000-fold concentration range using two cell health measure-
ment assays, one for cell viability and the other for cell death, to
differentiate between cytostatic and cytotoxic responses. For the
cell viability measurements in the 2D cell-based in vitro assays,
we used the luciferase-based cellular ATP detection reagent
CellTiter-Glo (Promega); and for the cell death detection, the cell
impermeable DNA-binding dye CellTox Green (Promega) was used
[25]. Fig. S1 shows the distribution of the 310 approved drugs and
investigational compounds, and Table S1 lists the 20 TNBC cell
lines.
The drug sensitivity score (DSS) was calculated to quantify both
the potency and the efficacy of the drug sensitivity of a cell line to a
compound treatment. DSS was calculated for each cell line and
compound pairs separately as the integral of the dose-response
curve, which is modelled by logistic function through drug-cell
responses under multiple doses [13]. For a given protein target,te deviation (MAD) of all drug-target pairs was first calculated within each category
e score for this group. Furthermore, the confidence score for Ki-Biochemical is the
was calculated the same way.
Fig. 11. Illustration of the calculation of target addiction score (TAS) for each protein target.
T. Wang, P. Gautam, J. Rousu et al. Computational and Structural Biotechnology Journal 18 (2020) 3819–3832the target addiction score (TAS) was calculated as the average DSS
of compounds known to target the protein (illustrated in Fig. 11),
using 1000 nM as an activity cut-off value for the summarized
compound-target bioactivities. TAS estimates the sensitivity of a
cell line to the pharmacological inhibition of the protein target,
as a measure of functional dependency of the cell line on the ther-
apeutic target. DSS and TAS provide druggable insights into vulner-
abilities of individual cells to therapeutic treatments and targets
and were calculated as described before [13,17].4.3. Identification of key protein target and protein groups in the TNBC
cell lines
In the present work, we estimated the statistical significance of
each observed TAS value by calculating empirical p-value using a
permutation test. This is important, since the observed TAS values
may not be directly comparable between studies, where different
compound libraries are used, or between cell lines that have differ-
ent compound response profiles. In contrast, p-values take into
account such between study or cell line differences. Permutation
tests for TAS values were carried out by randomizing compound-
target interactions, while keeping the number of interactions for
each drug unchanged. Permutation testing makes it possible to
compare response profiles from drug testing experiments with dif-
ferent sizes of compound libraries. Targets having a high TAS, along
with a small empirical p-value calculated based on the permuta-
tion null distribution, are identified as functionally important tar-
gets for a particular cell line. Subsampling of compounds and
targets was also performed during the permutation test to find
when the empirical p-value calculation becomes unreliable, as
the number of compounds or targets decrease in the TAS
calculation.
Publicly available gene essentiality scores based on CRISPR-
Cas9 screens were obtained from the Dependency Map database
(Release DepMap 19Q3) for the overlapping TNBC cell lines
[27,28]. For each protein target, the available gene dependency
score (CERES score) was matched by the HGNC official gene symbol
and compared with the corresponding TAS value.
For identification of protein groups, a protein-drug interaction
matrix was constructed, using summarized bioactivities from the
DTC database. Each row of the matrix represents a drug bioactivity
profile of a protein. If a protein-drug interaction potency is smaller
than 1000 nM, it is encoded as ‘‘1”, otherwise as ‘‘0”. Using these
binary drug profiles as features, all the proteins were mapped into
2D planes with the t-SNE method with L1 and L2 norms as distance
metrics, respectively [51]. Proteins constantly appeared as groups
across all the parameters of the t-SNE methods were manually
picked as groups of interests. For specific cell lines, the key action-
able protein groups were identified as those with more than 3
active drugs and significant TAS values (p < 0.05). Protein targets,
pre-ranked by their p-values in each cell line, were mapped onto3831KEGG pathways and Gene Ontology (GO) biological processes to
provide further mechanistic information, using the gene set enrich-
ment analysis (GSEA) [52], implemented through GSEApy python
package (github.com/zqfang/GSEApy).
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